Ross Osborn
Stock Analyst at Cantor Fitzgerald
(2.00)
# 3,119
Out of 5,042 analysts
118
Total ratings
29.36%
Success rate
-1.8%
Average return
Main Sectors:
Stocks Rated by Ross Osborn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRE Prenetics Global | Maintains: Overweight | $26 → $32 | $14.82 | +115.92% | 8 | Oct 29, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Overweight | $7 → $9 | $4.25 | +111.76% | 4 | Aug 8, 2025 | |
| LMAT LeMaitre Vascular | Maintains: Neutral | $92 → $95 | $86.54 | +9.78% | 2 | Aug 6, 2025 | |
| CVRX CVRx, Inc. | Reiterates: Overweight | $11 | $10.19 | +7.95% | 3 | Aug 5, 2025 | |
| SIBN SI-BONE | Reiterates: Overweight | $25 | $14.83 | +68.58% | 10 | Aug 5, 2025 | |
| MDXG MiMedx Group | Maintains: Overweight | $11 → $12 | $7.65 | +56.86% | 5 | Jul 31, 2025 | |
| BVS Bioventus | Initiates: Overweight | $12 | $6.55 | +83.21% | 1 | Jul 7, 2025 | |
| XGN Exagen | Maintains: Overweight | $8 → $7 | $11.67 | -40.02% | 6 | May 15, 2025 | |
| LUCD Lucid Diagnostics | Reiterates: Overweight | $2 | $1.21 | +65.29% | 6 | May 15, 2025 | |
| NPCE NeuroPace | Reiterates: Overweight | $17 | $9.94 | +71.03% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $3.63 | +147.93% | 11 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $46 | $29.30 | +57.00% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $0.91 | +779.70% | 10 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $22.22 | +8.01% | 3 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.47 | +172.11% | 4 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $4.49 | +100.45% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $3.87 | +442.64% | 10 | Dec 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $5.23 | +205.93% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3.5 | $2.34 | +49.57% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $0.43 | +476.04% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.48 | - | 7 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8.61 | $0.43 | +1,907.46% | 2 | Aug 18, 2023 |
Prenetics Global
Oct 29, 2025
Maintains: Overweight
Price Target: $26 → $32
Current: $14.82
Upside: +115.92%
Organogenesis Holdings
Aug 8, 2025
Maintains: Overweight
Price Target: $7 → $9
Current: $4.25
Upside: +111.76%
LeMaitre Vascular
Aug 6, 2025
Maintains: Neutral
Price Target: $92 → $95
Current: $86.54
Upside: +9.78%
CVRx, Inc.
Aug 5, 2025
Reiterates: Overweight
Price Target: $11
Current: $10.19
Upside: +7.95%
SI-BONE
Aug 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $14.83
Upside: +68.58%
MiMedx Group
Jul 31, 2025
Maintains: Overweight
Price Target: $11 → $12
Current: $7.65
Upside: +56.86%
Bioventus
Jul 7, 2025
Initiates: Overweight
Price Target: $12
Current: $6.55
Upside: +83.21%
Exagen
May 15, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $11.67
Upside: -40.02%
Lucid Diagnostics
May 15, 2025
Reiterates: Overweight
Price Target: $2
Current: $1.21
Upside: +65.29%
NeuroPace
May 14, 2025
Reiterates: Overweight
Price Target: $17
Current: $9.94
Upside: +71.03%
Apr 1, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $3.63
Upside: +147.93%
Mar 26, 2025
Reiterates: Overweight
Price Target: $46
Current: $29.30
Upside: +57.00%
Mar 7, 2025
Reiterates: Overweight
Price Target: $8
Current: $0.91
Upside: +779.70%
Mar 5, 2025
Reiterates: Overweight
Price Target: $24
Current: $22.22
Upside: +8.01%
Feb 21, 2025
Reiterates: Overweight
Price Target: $4
Current: $1.47
Upside: +172.11%
Jan 7, 2025
Initiates: Overweight
Price Target: $9
Current: $4.49
Upside: +100.45%
Dec 24, 2024
Reiterates: Overweight
Price Target: $21
Current: $3.87
Upside: +442.64%
Nov 5, 2024
Reiterates: Overweight
Price Target: $16
Current: $5.23
Upside: +205.93%
Aug 8, 2024
Reiterates: Overweight
Price Target: $3.5
Current: $2.34
Upside: +49.57%
May 16, 2024
Reiterates: Overweight
Price Target: $2.5
Current: $0.43
Upside: +476.04%
Apr 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $1.48
Upside: -
Aug 18, 2023
Reiterates: Neutral
Price Target: $8.61
Current: $0.43
Upside: +1,907.46%